Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379981575> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4379981575 endingPage "79" @default.
- W4379981575 startingPage "78" @default.
- W4379981575 abstract "Introduction: Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with dismal outcomes. Standard CHOP (Cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy is still the most widely used regimen for front-line management. To explore new targeted drugs in PTCL, we conducted a phase 2, multi-center, non-randomized clinical trial, comparing the efficacy and safety of targeted agents combined with CHOP (CHOPX) with CHOP in newly diagnosed patients with PTCL. Methods: The primary outcome was complete response rate (CRR) at the end of treatment (EOT). Patients with newly diagnosed PTCL had enough tumor tissue for next generation sequencing (NGS) and were assigned to CHOPX and CHOP group based on investigators’ discretion. Patients in CHOPX group received intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1.4 mg/m2 (up to a maximum of 2 mg) on day 1, and oral prednisone 60 mg/m2 (up to a maximum of 100 mg) on day 1–5 every 21 days at the first cycle. X (i.e., targeted agent) was added from the second to sixth cycles as following, intravenous decitabine 10 mg/m2 on day -5 to -1 if with TP53 mutation. Subcutaneous azacytidine 100 mg on day −7 to −1 if with TET2/KMT2D mutation. Oral chidamide 20 mg on day1, 4, 8, 11 if with CREBBP/EP300 mutation. Oral lenalidomide 25 mg on day 1–10 if without above mutations. Patients in control group received standard CHOP regimen for 6 cycles. Analysis of efficacy and safety was of the intent-to-treat population. The study was registered with ClinicalTrials.gov, number NCT04480099. Results: Between 20 June 2020 and 22 September 2022, 108 patients were assessed for eligibility in the study. Ten patients met exclusion criteria and 2 patients withdrew informed consent before treatment. Forty-eight patients in the CHOPX group and 48 patients in the CHOP group were included into intent-to-treatment population. Baseline patient characteristics like age, gender, Ann Arbor stage, performance status, prognostic risk group was comparable between CHOPX and CHOP groups. The most common pathological subtypes were angioimmunoblastic T-cell lymphoma (67% vs. 60%), PTCL-not otherwise specified (17% vs. 21%), anaplastic T-cell lymphoma (6% vs. 8%) in the CHOPX and CHOP groups. As of 1 February 2023, 91 patients completed response evaluation at EOT. CRR in the CHOPX group was higher than the CHOP group (58% [25/43] vs. 33% [16/48]). The most common grade 3–4 hematological adverse events in CHOPX group were neutropenia (61%) and febrile neutropenia (27%). Conclusions: Preliminary analysis showed targeted agents combined with CHOP was effective and safe compared with standard CHOP in PTCL. Therapeutic strategy specifically towards molecular features may change current PTCL management in front-line setting. Keywords: combination therapies, molecular targeted therapies No conflicts of interests pertinent to the abstract." @default.
- W4379981575 created "2023-06-10" @default.
- W4379981575 creator A5005839192 @default.
- W4379981575 creator A5016042589 @default.
- W4379981575 creator A5021146920 @default.
- W4379981575 creator A5032104899 @default.
- W4379981575 creator A5055807567 @default.
- W4379981575 creator A5056208588 @default.
- W4379981575 creator A5065668771 @default.
- W4379981575 creator A5069739901 @default.
- W4379981575 creator A5077666079 @default.
- W4379981575 creator A5086212262 @default.
- W4379981575 creator A5088855831 @default.
- W4379981575 creator A5089850088 @default.
- W4379981575 date "2023-06-01" @default.
- W4379981575 modified "2023-10-12" @default.
- W4379981575 title "TARGETED AGENTS COMBINED WITH CHOP COMPARED WITH CHOP AS THE FIRST‐LINE THERAPY FOR PERIPHERAL T‐CELL LYMPHOMA: PRELIMINARY RESULTS FROM A PHASE 2 GUIDANCE‐03 TRIAL" @default.
- W4379981575 doi "https://doi.org/10.1002/hon.3163_42" @default.
- W4379981575 hasPublicationYear "2023" @default.
- W4379981575 type Work @default.
- W4379981575 citedByCount "0" @default.
- W4379981575 crossrefType "journal-article" @default.
- W4379981575 hasAuthorship W4379981575A5005839192 @default.
- W4379981575 hasAuthorship W4379981575A5016042589 @default.
- W4379981575 hasAuthorship W4379981575A5021146920 @default.
- W4379981575 hasAuthorship W4379981575A5032104899 @default.
- W4379981575 hasAuthorship W4379981575A5055807567 @default.
- W4379981575 hasAuthorship W4379981575A5056208588 @default.
- W4379981575 hasAuthorship W4379981575A5065668771 @default.
- W4379981575 hasAuthorship W4379981575A5069739901 @default.
- W4379981575 hasAuthorship W4379981575A5077666079 @default.
- W4379981575 hasAuthorship W4379981575A5086212262 @default.
- W4379981575 hasAuthorship W4379981575A5088855831 @default.
- W4379981575 hasAuthorship W4379981575A5089850088 @default.
- W4379981575 hasBestOaLocation W43799815751 @default.
- W4379981575 hasConcept C126322002 @default.
- W4379981575 hasConcept C141071460 @default.
- W4379981575 hasConcept C143998085 @default.
- W4379981575 hasConcept C2776063141 @default.
- W4379981575 hasConcept C2776364478 @default.
- W4379981575 hasConcept C2776694085 @default.
- W4379981575 hasConcept C2776755627 @default.
- W4379981575 hasConcept C2778720950 @default.
- W4379981575 hasConcept C2779338263 @default.
- W4379981575 hasConcept C2779429289 @default.
- W4379981575 hasConcept C2779725641 @default.
- W4379981575 hasConcept C2781413609 @default.
- W4379981575 hasConcept C71924100 @default.
- W4379981575 hasConcept C90924648 @default.
- W4379981575 hasConceptScore W4379981575C126322002 @default.
- W4379981575 hasConceptScore W4379981575C141071460 @default.
- W4379981575 hasConceptScore W4379981575C143998085 @default.
- W4379981575 hasConceptScore W4379981575C2776063141 @default.
- W4379981575 hasConceptScore W4379981575C2776364478 @default.
- W4379981575 hasConceptScore W4379981575C2776694085 @default.
- W4379981575 hasConceptScore W4379981575C2776755627 @default.
- W4379981575 hasConceptScore W4379981575C2778720950 @default.
- W4379981575 hasConceptScore W4379981575C2779338263 @default.
- W4379981575 hasConceptScore W4379981575C2779429289 @default.
- W4379981575 hasConceptScore W4379981575C2779725641 @default.
- W4379981575 hasConceptScore W4379981575C2781413609 @default.
- W4379981575 hasConceptScore W4379981575C71924100 @default.
- W4379981575 hasConceptScore W4379981575C90924648 @default.
- W4379981575 hasIssue "S2" @default.
- W4379981575 hasLocation W43799815751 @default.
- W4379981575 hasOpenAccess W4379981575 @default.
- W4379981575 hasPrimaryLocation W43799815751 @default.
- W4379981575 hasRelatedWork W1896861650 @default.
- W4379981575 hasRelatedWork W1921119956 @default.
- W4379981575 hasRelatedWork W1986487042 @default.
- W4379981575 hasRelatedWork W2004932524 @default.
- W4379981575 hasRelatedWork W2031021461 @default.
- W4379981575 hasRelatedWork W2044362603 @default.
- W4379981575 hasRelatedWork W2047206303 @default.
- W4379981575 hasRelatedWork W2087824134 @default.
- W4379981575 hasRelatedWork W2138201596 @default.
- W4379981575 hasRelatedWork W2143831053 @default.
- W4379981575 hasVolume "41" @default.
- W4379981575 isParatext "false" @default.
- W4379981575 isRetracted "false" @default.
- W4379981575 workType "article" @default.